use study

Series A Capital Raise in the biotech sector. Biotechs are notorious for needing massive fund dollars and offer a long road to revenue. But how is the opportunity valued when the opposite is true?

Boston BioPharm is a fully integrated science-driven pharmaceutical/OTC, medical food, and dietary ingredient development company. They offer technology that makes dietary ingredients bioavailable, backed by research that proves they are safe.

In terms of strategy, our challenge was taking a small company playing in a massive sector with no existing brand, and presenting them and their experience in convincing fashion.

Tactical challenge

Understanding and converting “sciencespeak" into “investorspeak"

It takes a science-nerd writer to understand “sciencespeak"

to determine what science-y messaging is irrelevant for the investor.

Fortunately we have our own senior science storyteller armed with a degree in molecular biology.

In this case, before the science-nerd writer was involved,

three separate sets of eyeballs are formulating your collaborative strategy

Strategy documents

Pre-discovery call with actual investors

Recorded meeting audio files

Transcribed meeting notes

Customized Storyboard

Client review calls

Internal verbal pitch

Storyboard review call

Contrary to common belief

investors are more focused on your market than your company. In the six slide examples below, not once is the company’s value solution touted. That’s investor-centric, not presenter-centric.

client quote

"Presentation Partners was able to look at our offering from an investment perspective, but also aligned resources that were familiar with our industry. The result was a compelling story that resonated with investors and provided a framework emphasizing why we will win in the marketplace. This has allowed us to start the conversations in the most productive way for all parties involved during our raise."